Firalis Group
  1. Companies
  2. Firalis Group
  3. Products
  4. Firalis - Model BIOPRED - Autoimmune ...

FiralisModel BIOPRED - Autoimmune Disorder Biomarker Panel

SHARE

As part of the European IMI BT-Cure consortium followed by the H2020 RABIOPRED program launched in 2016, FIRALIS launches its proprietary assay for the identification of markers related to inflammatory-autoimmune disorders.

Most popular related searches

The Firalis BIOPRED panel is the result of an intensive research with an intelligent data mining approach in cooperation with centers of excellence in the domain of inflammatory-autoimmune disorders. It is a targeted gene sequencing panel of 2155 mRNA targets identified in several resources for several disorders, especially for those diseases in which biologics are indicated. These mRNAs are especially associated with inflammatory and pro-inflammatory pathways, immune response pathways, interleukins, chemokines, growth factors, metalloproteinases, and many others. Thanks to the HTG EdgeSeq platform, allowing mRNA measurements without an RNA extraction step, the BIOPRED assay offers an innovative and sensitive solution to profile thousands of mRNA targets directly in the samples and with excellent analytical performance on various matrices.

  • FFPE Tissue:  10mm2 slide of 5 µm section
  • Cell line / PBMCs: from 5.000 cells
  • PAXgene: 500 µL
  • Whole blood: 500 μL
  • Extracted RNA:  > 15 ng
  • Serum/plasma: 400 µL, RNA extraction required
  • High multiplex assay: 2155 mRNAs measured simultaneously on up to 96 samples per run
  • Reduce samples input without RNA extraction
  • RUO assay with ongoing IVD qualification process
  • Support of personalized medicine and drug development programs
  • First class analytical performances for more accurate and faster results
  • Precision medicine tool for the prediction of non-response to anti-TNF alpha treatment for Rheumatoid Arthritis patients

This panel is intended for multiple application such as:

  • The investigation and identification of biomarker candidates for personalized therapy and for the support of drug development in various inflammatory-autoimmune disorders
  • The identification of signatures for stratification of patients suffering from inflammatory-autoimmune disorders

2155 mRNAs targets are implicated in major inflammatory and autoimmune pathway:

  • Inflammatory and pro-inflammatory pathways
  • Immune response pathways
  • Anti-TNF alpha and associated pathways
  • Interleukins
  • Chemokines Growth factors
  • Metalloproteinases and many others...
  • Ankylosing Spondylitis Rheumatoid arthritis
  • Sjögren’s syndrome
  • Systemic Sclerosis
  • Systemic Lupus Erythematosus
  • Crohn’s Disease
  • Ulcerative Colitis
  • All forms of Vasculitides Inflammatory Myopathies